AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
October 18, 2017
-
October 11, 2017- 16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET
-
October 09, 2017
-
September 28, 2017- Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates
-
September 27, 2017- MAVIRET is the first and only 8-week treatment for genotype 1 and 2 hepatitis C virus (HCV) infected patients without cirrhosis and who are new to DAA treatment* in Japan
-
September 18, 2017-- Results of a multicenter, open-label, randomized Phase 3 study of VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in combination with Rituxan® met the primary endpoint of prolonged progression-free survival compared with bendamustine in combination with Rituxan in patients with relapsed/refractory CLL
-
September 11, 2017- SELECT-BEYOND, the second study in the robust SELECT program, demonstrated positive results with both doses (15 mg and 30 mg once-daily) meeting the primary endpoints in a difficult-to-treat patient population, over half of whom had previously been treated with two or more biologics(1)
-
September 08, 2017
-
September 07, 2017- Study shows positive results for upadacitinib and no new safety signals detected[1]
-
September 06, 2017- In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse
-
August 03, 2017- MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment
-
August 02, 2017- Approval for the treatment of cGVHD is the sixth U.S. disease indication for the medication and the first therapy specifically approved for adults with cGVHD after failure of one or more lines of systemic therapy
-
July 28, 2017- MAVIRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*
-
July 28, 2017- Reports Second-Quarter Diluted EPS of $1.19 on a GAAP Basis; Adjusted Diluted EPS of $1.42, Reflecting Growth of 12.7 Percent
-
July 21, 2017- If approved, HUMIRA® will be the first biologic treatment option in the European Union for pediatric patients with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy
-
June 23, 2017- If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)(1)*
-
June 22, 2017
-
June 07, 2017- First Phase 3 clinical trial shows positive results for upadacitinib and a safety profile consistent with that observed in Phase 2 clinical trials (1)(2)(3)
-
June 05, 2017- IMBRUVICA effectively impacted cancerous cells while sparing non-cancerous white blood cells through one year of treatment
-
June 05, 2017- Data show 59 percent progression free survival and 74 percent overall survival in CLL/SLL patients treated with IMBRUVICA, with high-risk patients trending to have the most favorable outcome[1]
-
May 17, 2017- Multiple new data presentations in solid tumors and hematology underscore AbbVie's growing oncology portfolio
-
May 17, 2017- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain
-
May 14, 2017- Results from data presented at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) further suggest that risk factors typically associated with poor clinical outcomes may be less relevant with ibrutinib treatment
-
May 09, 2017- Phase 2 study showed positive results in a moderately to severely active Crohn's disease patient population, the majority of whom had previously failed two or more biologics
-
May 04, 2017- Phase 2 late-breaking study evaluates upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderately to severely active Crohn's disease, the majority of whom had failed two or more biologics
-
April 27, 2017- Reports First-Quarter Diluted EPS of $1.06 on a GAAP Basis; Adjusted Diluted EPS of $1.28, Reflecting Growth of 11.3 Percent
-
April 21, 2017- 95 percent of patients infected with genotype 3 (GT3) chronic hepatitis C virus (HCV), without cirrhosis and who are new to treatment, achieved SVR(12) with 8 weeks of treatment(1)
-
April 20, 2017- New data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment(1)
-
April 07, 2017- Elagolix, with or without add-back therapy, showed effective and rapid reduction of heavy menstrual bleeding compared to placebo in women with uterine fibroids
-
April 06, 2017
-
March 30, 2017- HUMIRA is now the first-and-only biologic treatment with fingernail psoriasis data in its U.S. prescribing information for moderate to severe chronic plaque psoriasis patients
-
March 14, 2017- Priority review granted in Japan, following EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively
-
February 27, 2017- CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis*
-
February 17, 2017
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
